From the Journals

Dieting and Gout: Intensive Weight Loss Not Especially Helpful for Symptoms


 

TOPLINE:

An intensive weight loss program is safe for individuals with gout and obesity but does not ease gout symptoms compared with a “control diet” with basic nutritional counseling.

METHODOLOGY:

  • Weight loss is recommended as a gout management strategy, despite little clinical evidence.
  • Researchers recruited 61 patients with gout and obesity to participate in a 16-week, randomized, nonblinded, parallel-group trial in Denmark.
  • A total of 29 participants were assigned to an intensive, low-calorie diet with provided meal replacements.
  • Another 32 participants were assigned to the “control diet” with basic nutritional counseling.

TAKEAWAY:

  • Patients in the intensive group lost more weight (−15.4 kg/34 lbs) than those the control group (−7.7 kg/17 lbs).
  • There were no differences in pain, fatigue, or gout flares between the two groups.
  • Weight loss was associated with reduction in serum urate (SU).
  • Patients in the intervention group had a numerically larger mean SU change (−0.6 mg/dL) than the control group (−0.3 mg/dL), but this difference was not statistically significant.

IN PRACTICE:

Weight loss can lower SU levels, but this did not translate to improved gout symptoms.

SOURCE:

Robin Christensen, PhD, and Kristian Zobbe, MD, PhD, of the Parker Institute at Bispebjerg and Frederiksberg Hospital in Copenhagen, Denmark, were co-first authors of the study, published on January 2, 2024, in Arthritis & Rheumatology.

LIMITATIONS:

The study had a relatively small sample size and short-term intervention period, which may have made it difficult to detect differences between the intervention and control groups. Patients in the control group lost a significant amount of weight, which also affected comparisons between the two groups.

DISCLOSURES:

Several of the authors disclosed financial relationships with pharmaceutical companies. The Parker Institute, which funded the study, is supported by grants from the Oak Foundation and the Danish Rheumatism Association.

A version of this article appeared on Medscape.com.

Recommended Reading

SGLT2 inhibitors linked with fewer gout flares in diabetes
MDedge Family Medicine
Gout: Suboptimal management a continuing problem
MDedge Family Medicine
FDA approves canakinumab for gout flares
MDedge Family Medicine
Diabetes drug class appears to reduce recurrent gout flares
MDedge Family Medicine
Colchicine still needed to prevent gout flares in allopurinol ‘start-low, go-slow’ strategy
MDedge Family Medicine
Adverse event rates compared for colchicine, NSAIDs when starting allopurinol for gout
MDedge Family Medicine
Approximately 20% of U.S. adults are diagnosed with arthritis
MDedge Family Medicine
Gout: Studies support early use of urate-lowering therapy, warn of peripheral arterial disease
MDedge Family Medicine
CPPD nomenclature is sore subject for gout group
MDedge Family Medicine
Evidence Grows for SGLT2 Inhibitors in Rheumatology
MDedge Family Medicine